It’s Really Hard Not to Hate the Pharmaceutical Industry

For indispensable reporting on the coronavirus crisis and more, subscribe to Mother Jones' newsletters.


Another day, another drug. Today comes news of Nitropress, a generic blood pressure drug that was priced at $44 per vial way back in 2013. Then it was sold to Marathon Pharmaceuticals, which raised the price to $257. A few months ago it was sold yet again, this time to Valeant Pharmaceuticals, which raised the price to $806. But no worries! According to a spokesman, no one will ever be denied this medication:

“These are drugs that are only used by hospitals — they are not sold in pharmacies — in accordance with specific surgical procedures. This means that whenever the protocol calls for use of these drugs, they are used. Patients are never denied these drugs when the protocols call for their use.”

And there you have it. Hospitals have to use it, and no one else makes it, so Valeant can charge whatever they want. Satisfied?

Anyway, Democrats are “demanding answers” from Valeant, which will probably do about as much good as it did when they demanded answers from Marathon last year about their price increase. Or all the other companies they’ve demanded answers from ever since 10x price increases became the pharmaceutical industry’s favorite new sport. That is to say, none.

It’s a funny thing. I’ve probably read just about every reason in the book explaining why national health care is supposed to be a terrible idea. Most of these reasons are pretty lousy—either unsupported by the evidence or else directly contradicted by it. But there’s one exception: the argument that a national health care plan would drive down the price of drugs—as it has everywhere else in the world—and this would stifle innovation in the pharmaceutical biz. There’s some real merit to this claim.

It’s not quite that simple, of course, and it would take a longish post to go through this topic in detail. Nonetheless, you can put me in the camp of those who want to tread pretty carefully when it comes to regulating pharmaceutical pricing. But these guys are sure making it hard to maintain that position, aren’t they?

Thank you!

We didn't know what to expect when we told you we needed to raise $400,000 before our fiscal year closed on June 30, and we're thrilled to report that our incredible community of readers contributed some $415,000 to help us keep charging as hard as we can during this crazy year.

You just sent an incredible message: that quality journalism doesn't have to answer to advertisers, billionaires, or hedge funds; that newsrooms can eke out an existence thanks primarily to the generosity of its readers. That's so powerful. Especially during what's been called a "media extinction event" when those looking to make a profit from the news pull back, the Mother Jones community steps in.

The months and years ahead won't be easy. Far from it. But there's no one we'd rather face the big challenges with than you, our committed and passionate readers, and our team of fearless reporters who show up every day.

Thank you!

We didn't know what to expect when we told you we needed to raise $400,000 before our fiscal year closed on June 30, and we're thrilled to report that our incredible community of readers contributed some $415,000 to help us keep charging as hard as we can during this crazy year.

You just sent an incredible message: that quality journalism doesn't have to answer to advertisers, billionaires, or hedge funds; that newsrooms can eke out an existence thanks primarily to the generosity of its readers. That's so powerful. Especially during what's been called a "media extinction event" when those looking to make a profit from the news pull back, the Mother Jones community steps in.

The months and years ahead won't be easy. Far from it. But there's no one we'd rather face the big challenges with than you, our committed and passionate readers, and our team of fearless reporters who show up every day.

We Recommend

Latest

Sign up for our newsletters

Subscribe and we'll send Mother Jones straight to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate

We have a new comment system! We are now using Coral, from Vox Media, for comments on all new articles. We'd love your feedback.